Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

4(66.7%)

N/A

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 3(4)

N/A(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT01399931Unknown

Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions

Role: collaborator

NCT00795613Phase 2Unknown

Positron Emission Tomography (PET)-Adapted Chemotherapy In Advanced Hodgkin Lymphoma (HL)

Role: collaborator

NCT01980498Phase 3Withdrawn

PEctin Rapid Fentanyl Efficacy Clinical Trial For pAin at Swallowing Undergoing radioTherapy

Role: collaborator

NCT01745549Not ApplicableCompleted

Efficacy, Safety and Satisfaction of the New Pen Needle 33 Gauge x 4 mm.

Role: lead

NCT01645124Phase 3Terminated

Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)

Role: lead

NCT01192711Phase 3Unknown

Insulin Administration Plus a Telemedicine System (Diabetes Interactive Diary - DID) vs Insulin Plus Common Practice

Role: lead

NCT01176149Phase 3Completed

Role Of Self-monitoring of Blood Glucose and Intensive Education in Patients With Type 2 Diabetes Not Receiving Insulin

Role: lead

All 7 trials loaded